

An Update on the Roche/Genentech (RG6042) HD Natural History Study

This 15-month observational study aims to further understand the role of mutant huntingtin protein in disease progression. There is no drug treatment in this study, as the goal is to understand the natural progression of HD. This study will include up to 100 participants with early manifest (Stage I and II) HD at up to 17 sites in Canada, Germany, the United Kingdom and the United States.

Setup has progressed well in all four countries in which the HD Natural History Study is planned (Canada, Germany, UK and USA). The first countries to open recruitment will be Canada and the USA, and today we are sharing a list of planned sites.

Canada

British Columbia, Vancouver - University of British Columbia
Ontario, Toronto - Centre for Movement Disorders

United States of America

California, Sacramento - University of California Davis
Colorado, Englewood - Rocky Mountain Movement Disorders Center
District of Columbia, Washington - Georgetown University
Kansas, Wichita - Hereditary Neurological Disease Centre
Maryland, Baltimore - Johns Hopkins University
New York, New York - Columbia University
Texas, Houston - University of Texas

These sites are not fully activated or recruiting yet, but we hope to complete the final steps as quickly as possible. Information about planned sites in Germany and the UK for the HD Natural History Study will be shared when those sites are near activation and ready to enroll patients.

For all patients who complete the HD Natural History study, an open-label extension study with the option of receiving RG6042 (no placebo control) is planned, pending approval by Authorities and Ethics Committees/Institutional Review Boards and if data support the continued development of RG6042.

The decision to join a clinical trial is personal and involves many factors. We encourage anyone interested in participating in any clinical research to discuss with his/her HD specialist about what may be best for his/her situation.

More information about the study (Clinical Trials ID: NCT03664804) and these sites will soon be posted on [ClinicalTrials.gov](https://clinicaltrials.gov), including individual site status. Our Clinical Trial Information Support Line for Canada and the USA can also be contacted at 1-888-662-6728.